Click here for Besponsa®▼ (inotuzumab ozogamicin) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Evaluate VOD Risk
Proactively manage VOD
†May include cases which occurred in follow-up with subsequent anticancer therapy (e.g. maintenance therapy), but without or before intervening HSCT (VOD/SOS onset was before post-study therapy HSCT or there was no post-study therapy HSCT)3.
*5 cases were fatal.
‡Up to 56 days after final dose or during follow-up without an intervening HSCT.
Monitor closely for signs and symptoms of VOD/SOS, especially after allogeneic HSCT
Monitor ALT, AST, total bilirubin and ALP before and after each dose
Avoid HSCT conditioning regimens containing two alkylating agents
For patients >65 years and those at greater risk of VOD, carefully consider the benefit/risk of BESPONSA before administration
ALL, acute lymphoblastic leukaemia; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HSCT, haematopoietic stem cell transplantation; SoC, standard chemotherapy; SOS, sinusoidal obstruction syndrome; VOD, veno-occlusive disease
Download the guide for Pharmacists for information on dosing, drug interactions, reconstitution, administration, shelf life etc. SmPC should be consulted for full guidance.
Download the fast facts PDF document to aid your understanding of BESPONSA. SmPC should be consulted for full guidance.
Access Support and Resources to download clinical papers or watch videos from leading specialists.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020